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OBJECTIVE—The complexity of interactions between genes
and the environment is a major challenge for type 1 diabetes
studies. Nuclear chromatin is the interface between genetics and
environment and the principal carrier of epigenetic information.
Because histone tail modiﬁcations in chromatin are linked to
gene transcription, we hypothesized that histone methylation
patterns in cells from type 1 diabetic patients can provide novel
epigenetic insights into type 1 diabetes and its complications.
RESEARCH DESIGN AND METHODS—We used chromatin
immunoprecipitation (ChIP) linked to microarray (ChIP-chip)
approach to compare genome-wide histone H3 lysine 9 dimethy-
lation (H3K9me2) patterns in blood lymphocytes and monocytes
from type 1 diabetic patients versus healthy control subjects.
Bioinformatics evaluation of methylated candidates was per-
formed by Ingenuity Pathway Analysis (IPA) tools.
RESULTS—A subset of genes in the type 1 diabetic cohort
showed signiﬁcant increase in H3K9me2 in lymphocytes but not
in monocytes. CLTA4, a type 1 diabetes susceptibility gene, was
one of the candidates displaying increased promoter H3K9me2 in
type 1 diabetes. IPA identiﬁed two high-scoring networks that
encompassed genes showing altered H3K9me2. Many of them
were associated with autoimmune and inﬂammation-related
pathways, such as transforming growth factor-, nuclear factor-
B, p38 mitogen-activated protein kinase, toll-like receptor, and
interleukin-6. IPA also revealed biological relationships between
these networks and known type 1 diabetes candidate genes.
CONCLUSIONS—The concerted and synergistic alteration of
histone methylation within the identiﬁed network in lymphocytes
might have an effect on the etiology of type 1 diabetes and its
complications. These studies provide evidence of a novel asso-
ciation between type 1 diabetes and altered histone methylation
of key genes that are components of type 1 diabetes–related
biological pathways and also a new understanding of the pathol-
ogy of type 1 diabetes. Diabetes 57:3189–3198, 2008
T
ype 1 diabetes is an autoimmune disease result-
ing from complex interactions between genetic
and environmental factors. It is characterized by
T-cell–mediated destruction of the insulin-pro-
ducing -cells of pancreatic islets. More than 30 genome
loci have been linked to type 1 diabetes susceptibility
through genome linkage analysis (1). Although numerous
genetic studies, including the recent genome-wide associ-
ation study (2), have provided a wealth of knowledge
about genetic factors associated with type 1 diabetes, the
underlying mechanisms and pathways causing type 1
diabetes remain only partly understood (3). Genetic ap-
proaches in general cannot fully take into consideration
the interplay between genes and the environment in type 1
diabetes. As such, a study of the role of epigenetics in type
1 diabetes can provide valuable new insights.
Nuclear chromatin is a crucial interface between the
effects of genetics and environment and the principal
carrier of epigenetic information. The chromatin is con-
stantly affected by environmental stimuli, such as diet,
chemicals, and pathogens (4). The basic repeat unit of
chromatin is the nucleosome, which consists of two
copies each of histones H2A, H2B, H3, and H4 and is
wrapped by 147 bp DNA (5). Notably, the posttranslational
modiﬁcations (PTMs) of histone tails in chromatin have
been linked to gene transcription (6,7). The “histone code”
hypothesis has changed our view of histones as being
mainly a DNA scaffold to a key regulatory layer of gene
transcription. By interacting with various chromatin fac-
tors and regulatory proteins, histone PTMs can alter the
architecture of chromatin and gene expression. Abnormal
alterations in these interactions that cause relatively stable
epigenetic changes at the chromatin level could lead to
dysregulated gene transcription, metabolic memory (8–
10), and disease progression. We sought to obtain evi-
dence for this by genome-wide mapping of a key
chromatin mark, histone H3 dimethylated at lysine 9
(H3K9me2). This mark, broadly spread within the human
genome, is generally associated with gene repression and
could either be a repressive mark in euchromatin or a
hallmark feature of heterochromatin (11–13).
Chromatin immunoprecipitation (ChIP) coupled to DNA
microarray analysis, or ChIP-chip, is a widely used ap-
proach for acquiring genome-wide information on histone
modiﬁcations (14–18). We recently implemented this ap-
proach to proﬁle and compare the variations in histone
H3K4me2 and H3K9me2 in human gene coding and CpG
island regions in THP-1 monocytes cultured in normal and
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DIABETES, VOL. 57, DECEMBER 2008 3189high glucose (19). We observed that the treatment of
monocytes with high glucose to mimic diabetic conditions
could lead to key variations in H3K9me2 in the promoter
and coding regions of several genes, including those
relevant to the pathogenesis of diabetes (19). In the
present study, we have used three types of microarrays
(CpG, cDNA, and promoter tiling arrays) to compare, for
the ﬁrst time to our knowledge, the H3K9me2 proﬁles of
blood lymphocytes and monocytes obtained directly from
type 1 diabetic patients versus healthy control subjects.
Analyses of the data revealed a group of genes showing a
striking alteration in histone H3K9me2 in the lymphocytes
of the type 1 diabetic patients relative to healthy control
subjects and their strong associations to type 1 diabetes. In
addition, by applying the bioinformatics software Ingenu-
ity Pathway Application (IPA), we uncovered key biolog-
ical relationships among a subset of genes in the
differentially methylated group and their relevance to type
1 diabetes.
RESEARCH DESIGN AND METHODS
Human subject enrollment. An informed consent form was obtained from
all volunteers before blood samples were drawn with an approved institu-
tional review board protocol at the City of Hope General Clinical Research
Center. We prospectively enrolled 16 volunteers into two groups, the ﬁrst with
9 patients having a diagnosis of type 1 diabetes for 10 years (median 16
years, range 11–52 years), and the second with 7 healthy volunteers. No
history of autoimmunity was reported in healthy control subjects, and their
autoantibody status was not tested. Patient demographics are shown in Fig.
1C. There were no statistically signiﬁcant differences between age or sex
proportion in the two comparison groups. Blood lymphocytes and monocytes
from these volunteers were separated using the Ficoll method as described
previously (20) (details provided in supplemental methods available in an
online appendix at http://dx.doi.org/10.2337/db08-0645). The purity was 85%
for both monocyte and lymphocyte fractions. Both cell types were used for
ChIP experiments.
DNA microarrays. Human 12K cDNA arrays were from the University of
Pennsylvania Functional Genomics Core, and human 12K CpG island arrays
(containing 12,192 CpG island clones) were from the Universal Health
Network Microarray Center (Toronto) as described previously (19,20). Human
promoter tiling arrays containing 24,659 well-characterized RefSeq genes were
from Roche Nimblegen.
ChIP and ChIP-chip experiments. Conventional ChIPs and the ChIP-chips
were performed as described previously (15). Puriﬁed blood monocytes and
lymphocytes from type 1 diabetic and healthy control subjects were cross-
linked and sonicated to shear DNA. One-tenth of total lysate was used for
“no-antibody” control. ChIPs were then performed with the anti–dimethyl-
histone H3K9 (Upstate Biotechnology). Details are provided in the supple-
mental methods in the online appendix.
Human promoter tiling arrays were hybridized, and the data were extracted
according to standard operating procedures by NimbleGen Systems. Signal-
Map software from NimbleGen Systems was used to visualize the array peaks.
Microarray data collection and statistical analysis of microarray data.
Microarray images were scanned with a GenePix 4000B scanner and quanti-
ﬁed with GenePix Pro version 4.1.1.31 (Molecular Devices, Sunnyvale, CA).
We then imported the raw data from GenePix into R/Bioconductor statistical
software (21–24). We powered our study to detect large differences in up- or
downregulation across all probes. Based on our previous results (20), we
found that the SD for lymphocyte ChIP-chip data in this population was 0.5
on the log2 scale in the healthy volunteers. Assuming a two-sided test at 0.05
and 80% power, approximately eight subjects in each group allowed us to
detect log2 effect sizes of 0.75 or greater (fold change of 1.68 or greater). We
excluded one normal subject after ChIP-chip because of technical problems
with the hybridization seen in Fig. 1B. We also excluded one type 1 diabetic
patient’s ChIP-chip data because of a history of prostate cancer. Full details of
the statistical analysis of microarray data are provided in the supplemental
methods in the online appendix.
Real-time quantitative PCRs. Real-time quantitative PCRs were performed
as described previously (19). Student’s t tests were used for statistical
analyses of the data. Sequences of primers are provided in the supplemental
methods in the online appendix.
IPA. Core bioinformatics analyses were performed by the IPA (www.ingenu-
ity.com). IPA is a knowledge repository of networks and biological relation-
ships that have been systematically encoded into ontology based on 200,000
original peer-reviewed articles. Details and technical requirements are avail-
able in the IPA Web site (25) and in the supplemental methods in the online
appendix.
RESULTS
ChIP-chip proﬁling of histone methylation in blood
cells of type 1 diabetic patients and healthy control
subjects. Fig. 1A demonstrates the experimental design
for this study. Primary lymphocytes and monocytes were
isolated from the peripheral blood of two cohorts, type 1
diabetic patients and healthy control subjects, and used
for ChIP assays with anti–dimethyl-histone H3K9.
Antibody-enriched DNA samples and no-antibody controls
were prepared from monocytes and lymphocytes of each
volunteer separately. They were then analyzed by ChIP-
chip by hybridizing to three microarray platforms, i.e., 12K
human cDNA, 12K CpG island, and promoter tiling arrays.
Because type 1 diabetes is an autoimmune and T-cell–
dysregulated disease, we sought to determine whether
lymphocytes isolated from type 1 diabetic patients exhibit
any variations in histone lysine methylation relative to
healthy control subjects. We ﬁrst proﬁled H3K9me2 in
lymphocytes from a group of type 1 diabetic patients and
healthy control subjects by ChIP-chip using human 12K
cDNA arrays. The hierarchical clustering analysis (Fig. 1B)
shows that this methylation mark has similar distribution
patterns in gene coding regions in lymphocytes among all
of the individuals of both groups despite age or sex as
recently noted (20). Interestingly, however, there is a
clearly visible and consistent cluster or subset of genes
showing increased H3K9me2 in lymphocytes of type 1
diabetic patients relative to healthy control subjects (Fig.
1B, see enlarged region for clarity). These data demon-
strate 1) that histone methylation distribution patterns in
speciﬁc human cells are relatively stable in multiple indi-
viduals despite age or sex; and 2) that a group of genes
consistently displays aberrant H3K9me2 patterns in lym-
phocytes of type 1 diabetic patients. These data support
our ChIP-chip approach to detect variations in histone
methylation patterns between two separate groups to
provide meaningful and disease-associated information.
Alterations of H3K9me2 between type 1 diabetic
patients and healthy control groups are visible in
lymphocytes but not in monocytes. To identify speciﬁc
genes whose histone H3K9me2 status showed differences
between type 1 diabetic patients and healthy control
subjects, we developed a two-step analysis procedure to
retrieve the genome-wide methylation alterations (details
in the supplemental methods in the online appendix). We
assumed that the histone methylation pattern is “normal”
in healthy control subjects and deﬁned “alteration” as the
differences in histone methylation when type 1 diabetic
patients were compared with healthy control subjects. In
the ChIP-chips with 12K cDNA arrays, signiﬁcance analy-
sis of microarrays (SAM) (26) showed distinct variations
in H3K9me2 between the two cohorts in their lymphocyte
populations (Fig. 2A, a)but not in monocytes (Fig. 2A, b).
Red points in Fig. 2A, a represent probes in which type 1
diabetic patients had higher methylation than healthy
control subjects (594 probes were reported within false
discovery rate [FDR]  1%); green points represent probes
in which healthy control subjects had higher methylation
than type 1 diabetic patients (174 probes were reported
within FDR 1%). In addition, the variations in H3K9me2
were type 1 diabetes speciﬁc because no statistically
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were grouped based on age or sex (Fig. 2A, c and d). Then,
based on our requirement of altered histone modiﬁcation
status and a twofold difference criteria (19), 193 of the 594
probes were increased by at least twofold, and these were
identiﬁed as “increased” H3K9me2 genes in the 12K cDNA
array. These are represented in the heatmap in Fig. 2A,
right panel, showing relative methylation levels between
type 1 diabetic patients and healthy control subjects.
Speciﬁcally, genes meeting our criteria are unmethylated
in healthy control subjects but have shifted to a methyl-
ated state in type 1 diabetic patients. Detailed gene infor-
mation is listed in supplementary Table S1 (available in the
online appendix). Unexpectedly, we could not identify the
“decreased” H3K9me2 candidate genes in the type 1 dia-
betic group because all of 174 probes from Fig. 2A
showing a decrease in H3K9me2 failed to meet our require-
ments of altered histone modiﬁcation status and a twofold
difference criteria. Thus, all 174 probes are in an unmeth-
ylated state in both cohorts.
   T1D patients       Healthy controls
lymphocytes or      lymphocytes or
     monocytes          monocytes
    ChIPed DNA                 ChIPed DNA
no antibody control     no antibody control
    Labelling with Cy5 or Cy3
Hybridization with DNA arrays 
     & data acquisition
                    Applying SAM Package 
Analysis of Variations in Histone methylation
Ingenuity Pathway Analysis
Demographics  Normal (N=7)  Diabetes (N=9)  p-value 
Median Age Years 
(Range) 43 (35 – 60)  60 (25 – 85)  0.25 
Gender Male/Female
% 29% / 71%  33% / 67%  0.84 
Median Hemoglobin A1c 
% (Range)  --  7.5% (5.4% - 10.5%)   
A                                                 
C
B
T1D     Healthy Control
Ratio 0  1  2
FIG. 1. Proﬁling histone lysine methylation in blood cells from type 1 diabetic (T1D) patients versus healthy control subjects. A: The overall
experimental design. B: Hierarchically clustered histone H3K9me2 proﬁles of lymphocyte samples from patients with type 1 diabetes and healthy
control subjects (columns) and 10,053 probes (rows). Of the total 12,055 probes in the 12K cDNA array, 2,002 probe signal intensities were below
the threshold limit of detection, and this yielded 10,053 probes. The region at the bottom showing clear differences in a subset of genes in type
1 diabetes is depicted in the enlarged section on the right. C: Demographics for the type 1 diabetic patients and healthy control subjects. SAM,
signiﬁcance analysis of microarrays. (Please see http://dx.doi.org/10.2337/db08-0645 for a high-quality digital representation of this ﬁgure.)
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CpG island arrays (Fig. 2B). Similar to the cDNA array
results (Fig. 2A), signiﬁcant increases in H3K9me2 were
noted at CpG island regions on a subset of genes in
lymphocytes but not monocytes (Fig. 2B, a and b), and
these variations were again speciﬁc to type 1 diabetes and
not dependent on age or sex (Fig. 2B, c and d). Speciﬁcally,
213 probes showing increased methylation were identiﬁed
(heatmap in Fig. 2B, right panel). The annotation of these
“altered” CpG island targets can be summarized as fol-
lows: 1) within promoters, 2) within gene exons or in-
trons, 3) within the genome but not close to any genes, and
4) blank or not found by the BLAST database. Detailed
gene information is listed in supplementary Table S2
(available in the online appendix).
Last, we performed ChIP-chips with human promoter
tiling arrays using pooled histone H3K9me2 ChIP–en-
riched samples from eight type 1 diabetic patients or seven
healthy control subjects. By using a microarray peak
detection program MPeak (27) (details in the supplemen-
tal methods in the online appendix), two sets of genes
were obtained that displayed H3K9me2 variations between
type 1 diabetic patients and healthy control subjects as
depicted in the representative heatmap in Fig. 3A. The
heatmap shows a sample mapping of H3K9me2 enrich-
ment at the ﬁrst 20 probes in the promoter tiling array. Red
areas represent high levels of methylation, whereas blue
areas represent no methylation or low levels of methyl-
ation. Fig. 3A, left panel, shows genes depicting higher
H3K9me2 in the type 1 diabetic group (hypermethylation),
and Fig. 3A, right panel, is the converse (hypomethyla-
tion). We next conﬁrmed that these results obtained by
computation analyses are compatible with those displayed
by SignalMap, a package provided by Nimblegen for
visualizing the promoter tiling array data as shown by
selected hyper- and hypohistone methylation genes in Fig.
3B. The complete lists of these two groups of genes are
detailed in supplementary Tables S3 and S4, available in
the online appendix. Interestingly, CTLA4, a known type
1 diabetes susceptibility gene (1), displayed higher
H3K9me2 at the promoter region in type 1 diabetic pa-
tients. Other interesting methylated genes include inter-
leukin-1A (IL-1A), CLCX3, tumor necrosis factor (TNF),
Notch4, MAP4K3, and RARA (Fig. 3B). It is notable that
we recently observed similar H3K9me2 changes at the
IL-1A promoter in type 1 diabetic patient monocytes and
in THP-1 monocyte cells cultured in high glucose.
Collectively, the ChIP-chip proﬁling with three microar-
ray formats (cDNA, CpG, and promoter tiling arrays)
clearly reveals distinct associations between altered his-
tone H3K9me2 and type 1 diabetes (Figs. 2 and 3).
Validation of the H3K9me2 alterations in the mi-
croarrays and evaluation of the expression of levels
of the corresponding histone K9 methytransferases
in type 1 diabetic patients versus healthy control
subjects. To validate the cDNA and CpG array results, 10
probes that displayed increases in H3K9me2 were selected
for follow-up conventional ChIP assays with quantitative
real-time PCRs (Fig. 4A). Nine of the 10 probes showed at
least a twofold increase, conﬁrming the accuracy of data
generated by our ChIP-chip proﬁling method.
We next tested whether dysregulated expression of key
histone H3K9 methyltransferases or demethylases is re-
sponsible for the observed increase in H3K9me2 in the
type 1 diabetic patients. G9a is reported to be the primary
histone methyltransferase responsible for H3K9me2
(28,29). Quantiﬁcation of lymphocyte levels of G9a mRNA
by quantitative PCR revealed no signiﬁcant differences
between type 1 diabetic patients and healthy control
subjects (Fig. 4B). In addition, recent studies show there
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FIG. 2. Analysis of histone H3K9 dimethylation alterations between type 1 diabetic patients (T1D) and healthy control subjects using signiﬁcance
analysis of microarrays (SAM). A: Human 12K cDNA array results. a: SAM analysis of type 1 diabetic versus healthy control lymphocytes. b: Type
1 diabetic versus healthy control monocytes. c: Older subjects (age >45) versus younger subjects (age <45). d: Men versus women. Right:
Heatmap of histone H3K9me2 in lymphocytes from type 1 diabetic patients versus healthy control subjects. B: Human 12K CpG array results. a:
SAM analysis of type 1 diabetic versus healthy control lymphocytes. b: Type 1 diabetic versus healthy control monocytes. c: Older subjects (age
>45) versus younger subjects (age <45). d: men versus women. Right panels in A and B are heatmaps ofH3K9me2 in lymphocytes from type 1
diabetic patients versus healthy control subjects. ES, espected score; OS, observed score. (Please see http://dx.doi.org/10.2337/db08-0645 for a
high-quality digital representation of this ﬁgure.)
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LSD1 with androgen receptor (30–32), that function as
cellular histone H3K9me2 demethylases. Again, we found
no signiﬁcant differences in their expression levels (Fig.
4B). These results indicate that the altered histone
H3K9me2 patterns observed in type 1 diabetic patients are
most likely not caused by differential levels of the related
H3K9 methylases or demethylases.
Alteration of histone H3K9me2 at CTLA4 promoter
regions reveals an epigenetic role in type 1 diabetes.
We next validated the promoter tiling array data. The
demonstrated link between CTLA4 polymorphisms and
type 1 diabetes prompted us to further corroborate the
association of CTLA4 with H3K9me2 and other chromatin
marks H3K4me3 and H3K4me2. We also analyzed the
genes encoding the related molecules CD28 and ICOS,
which have costimulatory functions, whereas CTLA-4
serves as an inhibitory receptor (33). CD28 and ICOS
showed very little or no H3K9me2 signals in the tiling array
(Fig. 4C). All three histone methylation marks were detect-
able at CTLA4, suggesting a complex histone PTM code at
the CTLA4 promoter region, which could be related to its
tightly controlled expression pattern in T-cells. Notably,
when type 1 diabetic patients and healthy subjects were
compared, increased H3K9me2 at the CTLA4 promoter
with reciprocal decreased H3K9me2 at the ICOS promoter
was noted (Fig. 3C, top, compare arrows). Furthermore,
by performing follow-up quantitative PCRs with H3K9me2
ChIP–enriched DNA from each individual, we conﬁrmed
that this increase in H3K9me2 at the CTLA4 promoter was
statistically signiﬁcant in type 1 diabetic versus the healthy
control groups (Fig. 4D, P  0.0023). Because H3K9me2 is
considered a repressive mark, the altered H3K9me2 could
imply lower CTLA4 and higher ICOS levels in activated
T-cells of type 1 diabetes or when they are stimulated.
Both scenarios are expected to enhance T-cell activation
in type 1 diabetes and are compatible with the key role of
dysregulated T-cell activation in type 1 diabetes.
IPA of the gene set showing altered histone
H3K9me2 in type 1 diabetes. To evaluate the relevance
of the genes displaying increased methylation in cells from
type 1 diabetic patients, it is essential to uncover links
between these genes and type 1 diabetes. However, as in
all microarray studies, it is a daunting task to ﬁnd biolog-
ical links between several hundred genes and type 1
diabetes and integrate them within a connected network.
Fortunately, powerful bioinformatics tools are now avail-
able. We selected the IPA software (www.Ingenuity.com)
to further analyze the candidate gene list generated by our
ChIP-chips (details in the supplemental methods in the
online appendix). Brieﬂy, the list of genes showing in-
creased histone methylation was imported into IPA to
construct networks of biological relationships, such as
direct physical, pathway, transcriptional, and enzymatic
T1D Controls T1D Controls
Hyper-methylation
Hypo-methylation
A                                                 B
Hyper-methylation Examples
CAMK4
NOTCH1
HOXA9
TNF
MAP4K4
RARA
UBE2N
TRIP13
IL1A
SLC17A4
CXCL3
RAD51AP
CTLA4
PTPN20B
Hypo-methylation Examples
T1D          Controls
T1D            Controls
FIG. 3. Promoter tiling array data showing variations of histone H3K9me2 between type 1 diabetic (T1D) patients and healthy control subjects
in human promoter regions. A: Heatmap of histone H3K9me2 variations in promoter tiling arrays. Histone H3K9me2 ChIPs from type 1 diabetic
patients and healthy control subjects (pooled from each group) were hybridized to human promoter tiling arrays (Nimblegen). Using the peak
detection program MPeak, we located which promoters on the genome depicted H3K9me2 changes and located their positions by identifying
clustered areas of probes that exhibit high ratio values. MPeak results were compiled and ﬁltered for signiﬁcant peaks with P values <0.05. A
threshold cutoff ratio of twofold was used to generate the set of peaks, and probe-level values were uploaded to GenePattern’s HeatMapImage
software to create the heatmaps. B: Selected examples of hyper- and hypomethylated genes are illustrated by SignalMap. (Please see
http://dx.doi.org/10.2337/db08-0645 for a high-quality digital representation of this ﬁgure.)
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each network computed by IPA indicates the likelihood of
the input genes in the network being found together
because of random chance.
We ﬁrst combined gene lists generated from both CpG
and cDNA arrays (supplementary Tables S1 and S2) for
IPA analysis because all of these genes showed an in-
crease H3K9me2 in type 1 diabetes. Among 307 genes in
this list, 162 were mapped to 10 different networks by IPA
(listed in supplementary Table S3). The top-scoring net-
work (Fig. 5A) with functions in gene expression, organ
development, cellular growth, and proliferation had the
highest IPA score of 64 compared with the remaining
networks. Speciﬁcally, this network consisted of 35 inter-
acting nodes (molecules) known to be involved in
peroxisome proliferator–activated receptor (PPAR), trans-
forming growth factor-, nuclear factor-B (NF-B), p38
mitogen-activated protein kinase, TLR, IL-6, and Wnt sig-
naling pathways (Fig. 5A; Table 1; cDNA and CpG array
data) that are associated with inﬂammatory and autoim-
mune diseases (34). It is noteworthy that this network is
enriched in key transcription factors, such as JUNB,
CREBBP, HOXD13, E2F1, ATF1, ELK3, and AR, and also
signaling kinases, such as MRK10, MAP3K7, and IRAK1.
Many of these have connections with immune and inﬂam-
matory responses and NF-B activation as seen under
diabetic conditions. E2F1 is recently identiﬁed as an
NF-B–mediated transcriptional activator (35). In addi-
tion, INS and IDE, known candidate genes for type 1 and
type 2 diabetes (1,36), are also present in this list.
Next, we used IPA to analyze the methylated genes from
the promoter tiling array (supplementary Tables S3 and
S4). A total of 214 genes were mapped to eight networks
(Table S5), and the highest scoring network with a score of
39 (Fig. 5B) is linked to immune response function (Table
S5). Most importantly, the major pathways involved in this
network also included PPAR, IL-10, NF-B, and IL-6 sig-
naling pathways (Table 1, promoter array data), which are
comparable with the results from the cDNA and CpG array
data. Together, the IPA bioinformatics approach demon-
strates that genes methylated in type 1 diabetes are
enriched in signaling and transcription factors. This sug-
gests that a concerted and synergistic alteration of histone
methylation within the identiﬁed networks can lead to a
coordinated perturbation of above-mentioned pathways in
lymphocytes and possibly affect the development of type 1
diabetes and its complications.
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FIG. 4. Validation of histone methylation alterations and quantiﬁcation of histone methylase/demethylase mRNA levels in type 1 diabetic patients
and healthy control subjects. A: Validation of histone methylation alterations in cDNA and CpG arrays. Conventional ChIPs were carried out on
selected candidate genes to verify the alterations in histone H3K9me2 observed from the ChIP-chip experiments. ChIP real-time quantitative PCR
analyses were performed with corresponding primers (listed in the supplemental methods in the online appendix). Results shown are means 
SE of triplet real-time PCRs. *P < 0.05 vs. healthy control subjects, by t tests. B: Real-time quantitative PCR quantiﬁcation of histone
methylase/demethylase mRNA levels. Total RNAs were prepared from the lymphocytes of six type 1 diabetic patients and six healthy control
subjects for mRNA quantiﬁcation by real-time quantitative PCR. -Actin was used as internal control. Data shown (mean  SE) are from two sets
of PCRs with each independent patient sample with each sample run in triplicate. C: Histone modiﬁcation status at CTLA-4, CD28, and ICOS
promoter regions in lymphocytes from type 1 diabetic patients and healthy control subjects. Pooled histone ChIPs from type 1 diabetic patients
and healthy control subjects were hybridized to human promoter tiling arrays, and the data were extracted according to standard operating
procedures of NimbleGen. Result was visualized by SignalMap. Arrows indicate hyper- or hypohistone methylation. D: Conventional ChIP
validation of H3K9me2 modiﬁcation status at CTLA4 promoter region in lymphocytes from individual type 1 diabetic patients and the healthy
control group. Data show results from typical standardized experiments to quantify the amount of speciﬁc modiﬁed ChIP DNA in type 1 diabetic
patient and healthy control population using real-time quantitative PCR. In this particular experiment, nine type 1 diabetic and seven healthy
control samples were included. The results indicate a signiﬁcantly greater H3K9me2 enrichment at the CTLA4 promoter region in the type 1
diabetic group relative to healthy control group (*P  0.0023 vs. healthy control subjects, by t tests).
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genes and type 1 diabetes candidate genes. To explore
potential relationships of our networks to known type 1
diabetes genes, we took advantage of the IPA database,
which has a collection of 62 type 1 diabetes–related genes
from previous documented research, including traditional
genetic studies (supplementary Table S8, available in the
online appendix). We used the pathway explorer feature in
IPA, which allowed us to query reported biological rela-
tionships between a network and a set of genes based on
peer-reviewed publications. As such, we explored the
biological relationship or connections between type 1
A B
Transcription
    Factors 
Nuclear receptor Cytokine
Kinase Enzyme
Others
FIG. 5. The networks of altered histone methylation genes created by IPA. The hypothetical networks generated by IPA based on the molecular
relationships, interactions, and pathway associations between the methylated candidate genes are shown in a graphical representation. A: The
top-scoring network consists of 35 focus genes generated from cDNA and CpG arrays data. B: The top-scoring network consists of 20 focus genes
generated from promoter tiling array data. Proteins are represented as nodes, and the biological relationship between two nodes is represented
as an edge (line), which includes interactions, activation, inhibition, proteolysis, phosphorylation, and transcription events. Continuous lines,
direct interaction; dotted lines, indirect interaction. A, activation/deactivation; RB, regulation of binding; PP, protein-protein binding; PD,
protein-DNA binding; I, inhibition; L, proteolysis; P, phosphorylation/dephosphorylation; T, transcription.
TABLE 1
Implicated canonical pathways affected by altered histone H3K9me2
Pathway Ratio Molecules
cDNA and CpG array
PPAR signaling 9.23E-02 CREBBP, INS, CITED2, NRIP1, TNFRSF1B, MAP3K7
Transforming growth factor- signaling 8.20E-02 CREBBP, INHBA, BMP2, BMP4, MAP3K7
NF-B signaling 5.45E-02 CREBBP, INS, IRAK1, BMP2, BMP4, MAP3K7
p38 mitogen-activated protein kinase
(MAPK) signaling 4.76E-02 ATF1, TNFRSF1B, MAP3K7
TLR signaling 4.35E-02 IRAK1, MAP3K7
IL-6 signaling 4.35E-02 TNFRSF1B, MAPK10, MAP3K7
SAPK/JNK signaling 2.74E-02 MAPK10, MAP3K7
WNT/-cat signaling 2.21E-02 CREBBP, WNT5A, MAP3K7
Promoter tiling array
FXR/RXR activation 6.25E-02 PON1, IL1A, NR1H4, RARA, IL1F10, TNF
PPAR signaling 5.26E-02 SRA1, IL1A, MAP4K4, IL1F10, TNF
Glutamate receptor signaling 5.97E-02 GRIN2A, CAMK4, SLC17A6, GRIK2
IL-10 signaling 5.88E-02 IL1A, MAP4K4, IL1F10, TNF
Hepatic cholestasis 3.09E-02 IL1A, NR1H4, RARA, IL1F10, TNF
IL-6 signaling 4.40E-02 IL1A, MAP4K4, IL1F10, TNF
LPS/IL1 inhibition of RXR function 3.08E-02 MGST1, SLC27A2, NR1H4, RARA, CPT1C, TNF
NF-B signaling 3.50E-02 IL1A, UBE2N, MAP4K4, IL1F10, TNF
LXR/RXR activation 3.70E-02 IL1A, IL1F10, TNF
Xenobiotic metabolism signaling 2.40E-02 AHRR, MGST1, SRA1, IL1A, CAMK4, TNF
p38 MAPK signaling 3.16E-02 IL1A, IL1F10, TNF
Death receptor signaling 3.28E-02 MAP4K4, TNF
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our two top-scoring networks from Fig. 5. Pathway ex-
plorer revealed as many as 162 biological connections
between them (supplementary Fig. S1, available in the
online appendix). By the order of the number of literature
ﬁndings of biological relationships, such as direct interac-
tions, transcription, translocation, activation, inhibition,
and binding regulation, 21 genes with known association
to type 1 diabetes, including IL-1B, IFN, CD28, IL-2,
IL-4, IL-10, IL-13, IL-18, LCK, VDR, and TAB2, were
found to have connections with genes from our two
top-scoring networks (Fig. 6A). Conversely, 15 genes with
altered histone methylation from our study were found to
have connections with known type 1 diabetes genes (Fig.
6B). These results suggest that the top-scoring networks
(Fig. 5) could inﬂuence type 1 diabetes through these
known type 1 diabetes genes (Fig. 6) and related pathways
(supplementary Fig. S1). This not only reafﬁrms the role of
cytokines and inﬂammation in type 1 diabetes but also
provides new mechanistic and epigenetic insights into the
pathology of type 1 diabetes.
DISCUSSION
Human peripheral blood is an easily accessible and non-
invasive source of primary human cells that has provided
valuable genetic and gene expression information for
modern medicine. In the current study, for the ﬁrst time to
our knowledge, we have performed ChIP-chip with pri-
mary blood cells to examine the correlations between
histone methylation and type 1 diabetes by comparing the
genome-wide H3K9me2 proﬁles in lymphocytes and mono-
cytes from type 1 diabetic patients versus healthy control
subjects. We observed that a distinct subset of genes in
lymphocytes from type 1 diabetic patients show altered
histone methylation and that these genes are relevant to
the pathology of type 1 diabetes.
It should be underscored that there are key differences
between histone methylation proﬁling and traditional
mRNA proﬁling. The latter has contributed to most of our
knowledge of dysregulated gene expression in human
diseases. But the instability of mRNA itself, the inherent
complexity of transcription networks, and the imbalanced
copy number of transcripts could mask the real identity of
a speciﬁc gene(s) that contributes to underlying human
diseases. Instead, proﬁling the unvaried copy number and
a semistable chromatin mark, such as histone lysine
methylation, could be an alternative that reveals the
chromatin and epigenetic status of genes in cells. Our
eventual prediction of how cells will respond to environ-
mental stimuli based on their histone methylation patterns
will be a key beneﬁt. Such epigenomic information could
be critical to unmask the underlying mechanisms and
pathways causing type 1 diabetes. Histone methylation has
recently been linked to cancers (11,37,38), and our recent
studies have suggested the relevance to diabetes (19,39).
Furthermore, we recently reported that epigenetic histone
methylation could be responsible for metabolic memory
and sustained diabetic vascular complications (40). Col-
lectively, these data support the study of histone methyl-
ation proﬁling and epigenomics to provide new insights
into the pathology of diabetes.
Key proteins that recognize and bind to H3K9me2,
including HP1, Suv39h1, G9a, SETDB1, histone deacety-
lases, and DNMT1, can play repressive roles in transcrip-
tion (29,41,42). The variations in histone H3K9me2 at gene
promoter and coding regions that we observed in this
study are likely due to the recruitment of G9a through an
unknown mechanism(s), because G9a is the primary his-
tone methylase responsible for H3K9me2 (29), or through
histone exchange during transcription (43). This event
might be a regulatory feedback inhibition process trig-
gered by the induction of active transcription of a subset
of genes. If so, the increased H3K9me2 in gene coding
regions implies a recent history of active transcription and
may serve as a restraint for subsequent transcription,
because of the repressive role of H3K9me2. Thus, one
scenario to explain our results is that genes in the network
were actively transcribed under diabetic conditions and
this leads to G9a/H3K9me2-mediated feedback repression.
One of the consequences would be that the expression of
these genes will be impaired in the subsequent activation
period when the cell receives stimulation signals. Such
mechanisms could be signiﬁcant contributors to the patho-
genesis of type 1 diabetes.
Understanding the complex interactions between genes
and the environment remains a signiﬁcant challenge for
diabetes and other common diseases. Type 1 diabetes is an
autoimmune disease suggested to result from a combina-
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FIG. 6. Biological relationships between type 1 diabetes–related genes and our top-scoring networks based on literature ﬁndings. Known type 1
diabetes–related genes (Table S6 in the online appendix) were queried for their biological relationships to the identiﬁed top-scoring networks
(Fig. 5A and B) from our study. The bar graphs show the number of biological relationships between type 1 diabetes–related genes and genes in
our networks based on literature ﬁndings. Genes are placed in the order of the number of biological relationships from highest (left) to lowest
(right). A: Relationships between type 1 diabetes–related genes with our genes. B: Relationships between our genes and type 1 diabetes–related
genes. All biological relationships can also been seen in supplementary Fig. S1 in the online appendix.
HISTONE METHYLATION IN TYPE 1 DIABETES
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conferred by an unknown number of genetic factors.
Several biochemical mechanisms have also been shown to
mediate the associated cellular dysfunction. Along with
DNA sequences, histone methylation and DNA methyl-
ation are integral information encoded in the chromatin
and epigenome. The growing appreciation of the associa-
tion between methylation alterations and human diseases
arises from the fact that histone methylations are semi-
stable and heritable in somatic cells despite their dynamic
nature and thus could have epigenetic effects. However,
the complete biological functions of histone methylation
need to be fully decoded to clearly predict how cells
decipher histone methylation patterns and how alterations
in these patterns can relate to disease states. Although the
impact of histone methylation variations on common
human diseases has been proposed (44,45), to our knowl-
edge, no single genome-wide study has addressed this
issue with cells directly from diabetic patients. The cur-
rent investigation with patient cells is supported by our
recent study with cells cultured in vitro, showing that
acute diabetic stimuli, such as high glucose, can perturb
histone methylation and, importantly, that key genes
showing altered methylation were diabetes-related (19).
The patients enrolled in the current study all had long-
standing type 1 diabetes. Therefore, the observed methyl-
ation variations could be related to either type 1 diabetes
or its complications. A recent study reveals that several
proinﬂammatory factors are present in the sera of recent-
onset type 1 diabetic patients (46). Thus, future studies
could determine whether recent-onset type 1 diabetic
patients have similar methylation variations. In addition,
while choosing control subjects, careful consideration
could be given for matching age, sex, geographical region,
and major histocompatibility complex haplotypes. Pre-
diabetic subjects could also be assessed. Overall, although
there is no doubt that genomic single nucleotide polymor-
phisms in multiple key genes play decisive roles in type 1
diabetes (1,2), we believe that alterations in epigenetic
marks, such as histone methylation, also play important
roles, especially when environmental factors inﬂuence
disease parameters. Such epigenetic changes might also
explain the metabolic memory phenomenon observed in
the Epidemiology of Diabetes Interventions Complications
trial (8,10) in which type 1 diabetic patients continued to
develop complications even after subsequent glycemic
control. Finally, although it is too early to conclude that
epigenetic factors are the causes or consequences of type
1 diabetes, our ChIP-chip genome-wide proﬁling provides
strong evidence of such connections and reveals an epi-
genetic role for histone H3K9me2 in the lymphocytes of
type 1 diabetic patients.
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